Ken Griffin Aquestive Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$2.4 - $5.09 $14,160 - $30,031	5,900 Added 10.89%	60,100 $299,000
Q2 2024 Aug 14, 2024	SELL	$2.31 - $4.5 $124,047 - $241,650	-53,700 Reduced 49.77%	54,200 $140,000
Q1 2024 May 15, 2024	BUY	$2.01 - $6.09 $216,476 - $655,893	107,700 Added 53850.0%	107,900 $459,000
Q4 2023 Feb 14, 2024	SELL	$1.29 - $2.47 $1,548 - $2,964	-1,200 Reduced 85.71%	200 $0
Q3 2023 Nov 14, 2023	BUY	$1.5 - $2.24 $900 - $1,344	600 Added 75.0%	1,400 $2,000
Q2 2023 Aug 14, 2023	BUY	$1.06 - $2.49 $530 - $1,245	500 Added 166.67%	800 $1,000
Q1 2023 May 15, 2023	SELL	$0.72 - $1.15 $360 - $575	-500 Reduced 62.5%	300 $0
Q4 2022 Feb 14, 2023	BUY	$0.77 - $1.18 $616 - $944	800 New	800 $0

122

46.8M

517K

207K

Ticker AQST
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,350,700
Market Cap $265M
Description
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.